期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 19, 期 4, 页码 459-467出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2021.7009
关键词
-
类别
Studies show that multiagent chemotherapy regimens can be used to manage locally advanced PDAC, helping to stage the disease. This paradigm shift has expanded the pool of patients eligible for curative intent resection.
Because of the biologic aggressiveness and late presentation of pancreatic ductal adenocarcinoma (PDAC), up to 80% of patients have locally advanced or metastatic disease at presentation. The success of multiagent chemotherapy regimens in the management of metastatic disease has been translated to patients with locally advanced PDAC. Both FOLFIRINOX (fluorouracil/folinic acid/irinotecan/oxaliplatin) and gemcitabine/nab-paclitaxel are used to downstage locally advanced PDAC to render it eligible for resection with curative intent. This paradigm shift has significantly expanded the pool of patients who are eligible for resection with curative intent. However, the generalizability of present studies and the patient selection process are unclear. This article provides an evidence-based review of patient selection considerations and management algorithms, and details our institution's approach to patients with locally advanced PDAC after preoperative chemotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据